Vivek S. Radhakrishnan: We have provided a comprehensive and contemporary review of immunotherapy in Hodgkin lymphoma
Vivek S. Radhakrishnan, Haematologic Oncologist at Cancer Care Group University Hospital of Southampton, recently shared on LinkedIn:
“Happy to share our recent publication in ESMO – European Society for Medical Oncology journal Cancer Treatment Reviews Elsevier. We have provided a comprehensive and contemporary review of immunotherapy in Hodgkin lymphoma. Conventional therapies with cytotoxic drugs and radiation have made Hodgkin lymphoma a highly curable cancer, although challenges remain from resistance to treatment manifested by refractory and relapsed disease, and from short- and long-term treatment-related morbidities. Antibody-based novel therapeutics hold the promise of further improvements in outcomes through more specific targeting and de-intensifying therapies. This review looks at the tumor antigen-directed immunotherapies and immune checkpoint inhibitors in this disease. Treatment approaches continue to evolve and refine to address #unmet needs in this disease.
I thoroughly enjoyed this effort, working with my ace colleague Jemma Longley, and guidance provided by Professor Peter Johnson, thank you to both!”
For the article click here.
Source: Vivek S. Radhakrishnan/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023